Search Results
192 results found-
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
These products are an important addition to CSL Seqirus' portfolio of in-licensed medicines in Australia, alongside our work in respiratory diseases, pandemic preparedness and antivenoms.
https://newsroom.csl.com/2025-03-03-CSL-Seqirus-and-Esperion-Sign-Licensing-Agreement-to-commercialise-Nexletol-R-bempedoic-acid-and-Nexlizet-R-bempedoic-acid-ezetimibe-in-Australia-and-New-Zealand -
CSL Seqirus, a Global Leader in Pandemic Preparedness and Outbreak Response, Signs an Agreement with the European Commission to Support Pandemic Preparedness Plans
https://newsroom.csl.com/ -
CSL's is recognized for our contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.
https://www.csl.com/research-and-development/r-and-d-capabilities -
We are committed to ensuring early and reliable supply of influenza vaccines using both egg and cell-based manufacturing technologies.
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus/csl-seqirus-manufacturing -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
Collaboration and license agreement with Arcturus Therapeutics aims to accelerate next-generation mRNA capabilities in influenza, pandemic preparedness and other selected respiratory viral pathogens -- including a near term COVID-19 vaccine that has recently reported interim results from a large Phase III efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favourable safety profile.
https://newsroom.csl.com/2022-11-02-Next-Generation-mRNA,-Gene-Therapy,-Plasma-Products,-Monoclonal-Antibodies,-and-Recent-Acquisitions-and-Collaborations-Highlight-CSL-R-D-Day-2022 -
We collaborate with industry, academia and others developing great products and technologies that have the capacity to address unmet public health need.
https://www.csl.com/partnering -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2024-05-01-CSL-Seqirus-and-ARS-Pharma-sign-agreement-to-commercialise-neffy-TM-adrenaline-nasal-spray-in-Australia-and-New-Zealand